Patents by Inventor Eric Tzy-Shi WANG

Eric Tzy-Shi WANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240060091
    Abstract: Autoregulatory systems that have been implemented to control the expression and activity of Cast 3d, including the activity of Cast 3d in vivo, thereby reducing collateral damage in cells at off-target sites (e.g., non-target messenger RNA transcripts. The autoregulatory system is in the form of a nucleic acid molecule comprising a zinc finger binding site, a promoter, and a nucleotide sequence encoding a Cast 3d fusion protein, and a transcriptional repressor domain, and wherein the Cast 3d fusion protein binds to the zinc finger binding site and represses transcription of the nucleotide sequence encoding the Cast 3d fusion protein.
    Type: Application
    Filed: December 17, 2021
    Publication date: February 22, 2024
    Applicant: University of Florida Research Foundation, incorporation
    Inventors: Eric Tzy-Shi Wang, Chase P. Kelley
  • Publication number: 20230304088
    Abstract: Aspects of the disclosure relate to methods and compositions (e.g., biomarkers) useful for diagnosing pre- symptomatic amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD), and for monitoring the progression of ALS/FTD in subjects diagnosed with the disease. Methods of treating neurodegenerative diseases (e.g., ALS/FTD) are also described.
    Type: Application
    Filed: May 14, 2021
    Publication date: September 28, 2023
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Laura Ranum, Amrutha Pattamatta, Eric Tzy-Shi Wang, Hailey Olafson
  • Publication number: 20220411821
    Abstract: Provided herein, in some embodiments, are nucleic acid constructs encoding RNA molecules comprising one or more introns that can be regulated (e.g., autoregulated), and that are useful for delivery in a recombinant viral vector. Aspects of the application provide compositions and methods for delivering regulated (e.g., auto-regulated) gem expression constructs to a subject.
    Type: Application
    Filed: October 28, 2020
    Publication date: December 29, 2022
    Applicant: University of Florida Research Foundation, Incorporated
    Inventors: Eric Tzy-Shi Wang, John Andrew Berglund, Elizabeth Delgado, Jana Rose Jenquin
  • Patent number: 11529358
    Abstract: Disclosed are methods of treating a disorder or disease associated with myotonic dystrophy. Methods of treating a CNS dysfunction and/or cognitive impairment associated with myotonic dystrophy in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of treating a myotonic dystrophy associated disease or disorder caused by mis-splicing of GABRG2 in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of improving cognitive function or alertness in a subject having myotonic dystrophy comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: December 20, 2022
    Assignees: Emory University, University of Florida Research Foundation, Inc.
    Inventors: Gary Bassell, Andrew Jenkins, David B. Rye, Maurice Scott Swanson, Eric Tzy-Shi Wang, Lyndon Lien
  • Publication number: 20210285010
    Abstract: Disclosed herein are compositions and methods for treating diseases characterized by expanded microsatellite repeats by impeding or inhibiting transcription of expanded microsatellite repeats.
    Type: Application
    Filed: October 31, 2017
    Publication date: September 16, 2021
    Inventors: Eric Tzy-Shi Wang, Tanvi Saxena, Belinda Pinto, John Andrew Berglund
  • Publication number: 20210023091
    Abstract: Disclosed are methods of treating a disorder or disease associated with myotonic dystrophy. Methods of treating a CNS dysfunction and/or cognitive impairment associated with myotonic dystrophy in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of treating a myotonic dystrophy associated disease or disorder caused by mis-splicing of GABRG2 in a subject comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed. Methods of improving cognitive function or alertness in a subject having myotonic dystrophy comprising administering a therapeutically effective amount of a GABAA receptor antagonist or inverse agonist to the subject are disclosed.
    Type: Application
    Filed: May 10, 2018
    Publication date: January 28, 2021
    Inventors: Gary BASSELL, Andrew JENKINS, David B. RYE, Maurice Scott SWANSON, Eric Tzy-Shi WANG, Lyndon LIEN